



an Open Access Journal by MDPI

New Advancements in Chronic Inflammatory Skin Disease

Guest Editors:

Dr. Francesca Prignano

Department of Health Sciences,
Section of Dermatology,
University of Florence, 50125
Florence, Italy

Dr. Antonella Di Cesare

Department of Health Sciences,
Section of Dermatology,
University of Florence School of
Medicine, Florence, Italy

Dr. Elia Rosi

Department of Health Sciences,
Section of Dermatology,
University of Florence School of
Medicine, Florence, Italy

Deadline for manuscript
submissions:

closed (31 August 2022)

Message from the Guest Editors

Chronic inflammatory skin diseases represent a great proportion of skin diseases, and the therapy in daily life is challenging. Most of these diseases (e.g., psoriasis, atopic dermatitis, hidradenitis suppurativa) are characterized by undertreatment and/or a great delay in correct diagnosis and proper treatment. Therefore, the quality of life of these patients is very poor. In recent years, many new biologics and small molecules have been introduced for the treatment of chronic inflammatory skin diseases, substantially changing the clinical profile of patients and in some cases avoiding the progression of the underlying disease. In some instances, to the great success of the clinical outcomes the quality of life has also improved as a consequence. On the other hand, as is the case with hidradenitis suppurativa, not all these efforts in research and development resulted in effective therapies. Understanding triggers may be crucial to increasing therapeutic effectiveness and preventing the exacerbation of these chronic conditions.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

Journal Rank: JCR - Q2 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](https://twitter.com/Biomed_MDPI)